Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions

Next Previous
Trial Profile

A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Probenecid (Primary)
  • Indications COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
  • Focus Pharmacokinetics
  • Sponsors TrippBio

Most Recent Events

  • 25 Nov 2024 Status changed from not yet recruiting to completed.
  • 08 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 Oct 2024.
  • 08 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top